subgroup analyses in the clear study of lenvatinib plus pembrolizumab versus sunitinib in rcc
Published 3 years ago • 437 plays • Length 1:58Download video MP4
Download video MP3
Similar videos
-
0:49
clear: lenvatinib and pembrolizumab in advanced renal cell carcinoma
-
0:59
combining lenvatinib & pembrolizumab for non-clear cell rcc: keynote-b61 study rationale
-
2:06
lenvatinib plus pembro for arcc - update on the clear study
-
2:06
updated analysis of keynote-426: pembro plus axitinib vs sunitinib in mrcc
-
4:47
keynote-426 - pembrolizumab plus axitinib versus sunitinib for mrcc
-
3:28
dr rini on a biomarker analysis for pembrolizumab/axitinib in advanced rcc
-
2:32
len pembro metastatic clear cell renal cell carcinoma
-
10:06
lenvatinib and pembrolizumab compared to sunitinib for advanced renal cell carcinoma
-
2:18
pembrolizumab monotherapy and pembro-axitinib for rcc
-
1:35
dr. george on the use of adjuvant sunitinib in rcc
-
2:31
axitinib plus pembrolizumab in advanced rcc
-
1:28
keynote-b61: first-line lenvatinib pembrolizumab in non-clear cell rcc
-
32:46
lenvatinib pembrolizumab in rcc, the clear trial with karine tawagi
-
3:03
adjuvant pembrolizumab improves rcc disease-free survival | toni choueiri
-
2:03
lesion responses to lenvatinib and pembrolizumab based on organ sites
-
6:42
the role of lenvatinib in advanced rcc
-
3:10
keynote-426 rationale and results: pembro plus axitinib vs. sunitinib in mrcc
-
2:38
checkmate 9er: cabo-nivo superior to sunitinib in extended follow-up results
-
2:30
dr. choueiri on the subgroup analysis of the javelin renal 101 trial in rcc